Xeris Pharmaceuticals (XERS) has provided an announcement.
During Xeris Biopharma Holdings, Inc.’s 2024 Annual Meeting, stockholders voted to amend the company’s 2018 Employee Stock Purchase Plan by removing the automatic annual share increase and adding 6,636,632 new shares. Additionally, they elected three Class III directors and ratified Ernst & Young LLP as the independent auditor for the fiscal year. Stockholders also favored annual advisory votes on executive compensation and endorsed the proposed executive pay. Votes on these proposals showcased strong shareholder involvement and support for the company’s strategic decisions.
See more insights into XERS stock on TipRanks’ Stock Analysis page.
